Pernille Lassen1, Hanne Primdahl2, Jørgen Johansen3, Claus A Kristensen4, Elo Andersen5, Lisbeth J Andersen6, Jan F Evensen7, Jesper G Eriksen8, Jens Overgaard8. 1. Department of Experimental Clinical Oncology, Aarhus University Hospital, Denmark. Electronic address: pernille@oncology.dk. 2. Department of Oncology, Aarhus University Hospital, Denmark. 3. Department of Oncology, Odense University Hospital, Denmark. 4. Department of Oncology, Rigshospitalet, Denmark. 5. Department of Oncology, Herlev Hospital, Copenhagen, Denmark. 6. Department of Oncology, Aalborg Hospital, Denmark. 7. Department of Oncology, Oslo University Hospital, Norway. 8. Department of Experimental Clinical Oncology, Aarhus University Hospital, Denmark.
Abstract
BACKGROUND AND PURPOSE: HPV is found in head and neck cancer from all sites with a higher prevalence in oropharynx cancer (OPC) compared to non-OPC. HPV/p16-status has a significant impact on radiotherapy (RT) outcome in advanced OPC, but less is known about the influence in non-OPC. We analyzed HPV-associated p16-expression in a cohort of patients with stage III-IV pharynx and larynx cancer treated with primary, curatively intended (chemo-)RT, aiming to test the hypothesis that the impact of HPV/p16 also extends to tumors of non-oropharyngeal origin. MATERIAL AND METHODS: 1294 patients enrolled in previously conducted DAHANCA-trials between 1992 and 2012 were identified. Tumors were evaluated by p16-immunohistochemistry and classified as positive in case of staining in >70% of tumors cells. RESULTS: Thirty-eight percent (490/1294) of the tumors were p16-positive with a significantly higher frequency in OPC (425/815) than in non-OPC (65/479), p<.0001. In OPC p16-positivity significantly improved loco-regional control (LRC) (adjusted HR [95% CI]: 0.43 [0.32-0.57]), event-free survival (EFS) (HR 0.44 [0.35-0.56]), and overall survival (OS) (HR: 0.38 [0.29-0.49]), respectively, compared with p16-negativity. In non-OPC no prognostic impact of p16-status was found for either endpoint: LRC (HR: 1.13 [0.75-1.70]), EFS (HR: 1.06 [0.76-1.47]), and OS (HR: 0.82 [0.59-1.16]). CONCLUSIONS: The independent influence of HPV-associated p16-expression in advanced OPC treated with primary RT was confirmed. However, RT-outcome in the group of non-OPC did not differ by tumor p16-status, indicating that the prognostic impact may be restricted to OPC only.
BACKGROUND AND PURPOSE: HPV is found in head and neck cancer from all sites with a higher prevalence in oropharynx cancer (OPC) compared to non-OPC. HPV/p16-status has a significant impact on radiotherapy (RT) outcome in advanced OPC, but less is known about the influence in non-OPC. We analyzed HPV-associated p16-expression in a cohort of patients with stage III-IV pharynx and larynx cancer treated with primary, curatively intended (chemo-)RT, aiming to test the hypothesis that the impact of HPV/p16 also extends to tumors of non-oropharyngeal origin. MATERIAL AND METHODS: 1294 patients enrolled in previously conducted DAHANCA-trials between 1992 and 2012 were identified. Tumors were evaluated by p16-immunohistochemistry and classified as positive in case of staining in >70% of tumors cells. RESULTS: Thirty-eight percent (490/1294) of the tumors were p16-positive with a significantly higher frequency in OPC (425/815) than in non-OPC (65/479), p<.0001. In OPC p16-positivity significantly improved loco-regional control (LRC) (adjusted HR [95% CI]: 0.43 [0.32-0.57]), event-free survival (EFS) (HR 0.44 [0.35-0.56]), and overall survival (OS) (HR: 0.38 [0.29-0.49]), respectively, compared with p16-negativity. In non-OPC no prognostic impact of p16-status was found for either endpoint: LRC (HR: 1.13 [0.75-1.70]), EFS (HR: 1.06 [0.76-1.47]), and OS (HR: 0.82 [0.59-1.16]). CONCLUSIONS: The independent influence of HPV-associated p16-expression in advanced OPC treated with primary RT was confirmed. However, RT-outcome in the group of non-OPC did not differ by tumorp16-status, indicating that the prognostic impact may be restricted to OPC only.
Authors: Brenda Y Hernandez; Charles F Lynch; Owen T M Chan; Marc T Goodman; Elizabeth R Unger; Martin Steinau; Trevor D Thompson; Maura Gillison; Christopher Lyu; Mona Saraiya Journal: Oral Oncol Date: 2019-03-05 Impact factor: 5.337
Authors: Huaising C Ko; Paul M Harari; Ryan M Sacotte; Shuai Chen; Aaron M Wieland; Menggang Yu; Andrew M Baschnagel; Justine Y Bruce; Randall J Kimple; Matthew E Witek Journal: J Cancer Res Clin Oncol Date: 2017-07-27 Impact factor: 4.553
Authors: Michael Baumann; Mechthild Krause; Jens Overgaard; Jürgen Debus; Søren M Bentzen; Juliane Daartz; Christian Richter; Daniel Zips; Thomas Bortfeld Journal: Nat Rev Cancer Date: 2016-03-18 Impact factor: 60.716
Authors: Carole Fakhry; William H Westra; Steven J Wang; Annemieke van Zante; Yuehan Zhang; Eleni Rettig; Linda X Yin; William R Ryan; Patrick K Ha; Alicia Wentz; Wayne Koch; Jeremy D Richmon; David W Eisele; Gypsyamber D'Souza Journal: Cancer Date: 2017-02-27 Impact factor: 6.860
Authors: Efterpi Kostareli; Thomas Hielscher; Manuela Zucknick; Lorena Baboci; Gunnar Wichmann; Dana Holzinger; Oliver Mücke; Michael Pawlita; Annarosa Del Mistro; Paolo Boscolo-Rizzo; Maria Cristina Da Mosto; Giancarlo Tirelli; Peter Plinkert; Andreas Dietz; Christoph Plass; Dieter Weichenhan; Jochen Hess Journal: Epigenetics Date: 2016-01-19 Impact factor: 4.528
Authors: Eva-Leonne Göttgens; Christian Ostheimer; Paul N Span; Jan Bussink; Ester M Hammond Journal: Br J Radiol Date: 2018-03-14 Impact factor: 3.039
Authors: Hong Li; Sina J Torabi; Wendell G Yarbrough; Saral Mehra; Heather A Osborn; Benjamin Judson Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-06-01 Impact factor: 6.223
Authors: Daniela Thorwarth; Stefan Welz; David Mönnich; Christina Pfannenberg; Konstantin Nikolaou; Matthias Reimold; Christian La Fougère; Gerald Reischl; Paul-Stefan Mauz; Frank Paulsen; Markus Alber; Claus Belka; Daniel Zips Journal: J Nucl Med Date: 2019-05-10 Impact factor: 10.057
Authors: Angela L Mazul; James M Taylor; Kimon Divaris; Mark C Weissler; Paul Brennan; Devasena Anantharaman; Behnoush Abedi-Ardekani; Andrew F Olshan; Jose P Zevallos Journal: Cancer Date: 2016-08-29 Impact factor: 6.860